As of 2025-05-18, the Intrinsic Value of Moberg Pharma AB (publ) (MOB.ST) is (6,483.27) SEK. This MOB.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 8.57 SEK, the upside of Moberg Pharma AB (publ) is -75,750.80%.
The range of the Intrinsic Value is (37,355.08) - (3,570.72) SEK
Based on its market price of 8.57 SEK and our intrinsic valuation, Moberg Pharma AB (publ) (MOB.ST) is overvalued by 75,750.80%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (37,355.08) - (3,570.72) | (6,483.27) | -75750.8% |
| DCF (Growth 10y) | (22,951.89) - (250,842.16) | (42,595.03) | -497124.8% |
| DCF (EBITDA 5y) | (943.45) - (2,269.19) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (6,645.09) - (16,040.90) | (1,234.50) | -123450.0% |
| Fair Value | -26.64 - -26.64 | -26.64 | -410.86% |
| P/E | (77.68) - (83.44) | (75.13) | -976.6% |
| EV/EBITDA | 3.48 - 1.99 | 2.59 | -69.8% |
| EPV | 1.14 - (0.45) | 0.34 | -96.0% |
| DDM - Stable | (107.02) - (1,392.03) | (749.52) | -8845.9% |
| DDM - Multi | (2,921.31) - (29,796.51) | (5,339.56) | -62405.2% |
| Market Cap (mil) | 410.33 |
| Beta | 0.36 |
| Outstanding shares (mil) | 47.88 |
| Enterprise Value (mil) | 121.19 |
| Market risk premium | 5.10% |
| Cost of Equity | 5.70% |
| Cost of Debt | 5.50% |
| WACC | 5.68% |